高级检索
当前位置: 首页 > 详情页

Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Radiology, West China Hospital, Sichuan University, No 37, Guoxue Alley, Chengdu 610041, Sichuan, China [2]Institute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China [3]Department of Research and Development, Shanghai United Imaging Intelligence Co., Ltd., Shanghai, China [4]Department of Radiology, Sanya People’s Hospital, Sanya, Hainan, China
出处:
ISSN:

关键词: Hepatocellular carcinoma SOX9 Sorafenib Radiomics Computed tomography

摘要:
To develop and validate a radiomics-based model for predicting SOX9-positive hepatocellular carcinoma (HCC) using preoperative contrast-enhanced computed tomography (CT) images.From January 2013 to April 2017, patients with histologically proven HCC who received systemic sorafenib treatment after curative resection were retrospectively enrolled. Radiomic features were extracted from portal venous phase CT images and selected to build a radiomics score using logistic regression analysis. The factors associated with SOX9 expression were selected and combined by univariate and multivariate analyses to establish clinico-liver imaging (CL) model and clinico-liver imaging-radiomics (CLR) model. Diagnostic performance was measured by area under curve (AUC). Overall survival (OS) and recurrence-free survival (RFS) rates were compared using Kaplan-Meier method.A total of 108 patients (training cohort: n = 80; validation cohort: n = 28) were enrolled. Multivariate analyses revealed that the albumin-bilirubin grade and tumor size were significant independent factors for predicting SOX9-positive HCCs and were included in the CL model. The CLR model integrating the radiomics score with albumin-bilirubin grade and tumor size showed better discriminative performance than the CL model with AUCs of 0.912 and 0.790 in the training and validation cohorts. Survival curves for RFS and OS showed that SOX9 expression was closely related to the prognosis of HCC patients. RFS and OS rates were significantly lower in patients with SOX9-positive than SOX9-negative (51.02% vs. 75.00% at 1-year RFS rates; 76.92% vs. 94.94% at 2-year OS rates).Radiomics signatures may serve as noninvasive predictors for SOX9 status evaluation in patients with HCC and may aid in constructing individualized treatment strategies.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 核医学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 核医学
第一作者:
第一作者机构: [1]Department of Radiology, West China Hospital, Sichuan University, No 37, Guoxue Alley, Chengdu 610041, Sichuan, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Radiology, West China Hospital, Sichuan University, No 37, Guoxue Alley, Chengdu 610041, Sichuan, China [4]Department of Radiology, Sanya People’s Hospital, Sanya, Hainan, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号